Quick Links
Contact
Safety services
B'SYS performs tests to identify drug interactions with cardiac ion channels that act as target for QT prolongation.
Central nervous safety tests involve targets that are involved in addiction and neurotoxicity. B'SYS conducts assays to determine single concentration activities or concentration response relationships of test compounds.
- Cardiac ion channel panel for identification and assessment of drugs that alter the QT interval
- Cardiomyocyte action potential assays
- Central nervous system panel for the identification of sedative, addictive or neurotoxic potential of test compounds.
- Cardiotoxicity Screening (MEA, impedance)
Cardiac Panel / Comprehensive in Vitro Proarrhytmia Assay (CiPA)
Nav1.5 (available as GLP assay) | SCN5A |
Nav1.5 late current | SCN5A |
Kv4.3 KChiP | KCND3 / KCNIP2 |
Cav1.2 (available as GLP assay) | CACNA1C / CACNB2 / CACNA2D |
hERG (available as GLP assay) | KCNH2 |
Kv7.1/minK | KCNQ1 / KCNQE1 |
Kir2.1 | KCNJ2 |
Cardiac Panel (Automated Patch Clamping)
Nav1.5 (available as GLP assay) | SCN5A |
Nav1.5 late current | SCN5A |
Kv4.3 KChiP | KCND3 / KCNIP2 |
Cav1.2 (available as GLP assay) | CACNA1C / CACNB2 / CACNA2D |
hERG (available as GLP assay) | KCNH2 |
Kv7.1/minK | KCNQ1 / KCNQE1 |
Kir2.1 | KCNJ2 |
Kv1.5 | KCNA5 |
Cav3.2 | CACNA1H |
Kv7.2 | KCNQ2 |
Kv7.2/7.3 (m current) | KCNQ2/3 |
Nav1.1 | SCN1A |
Nav1.2 | SCN2A |
Nav1.3 | SCN3A |
Nav1.6 | SCN8A |
Nav1.7 | SCN9A |
Nav1.8 | SCN10A |
Neuroblastoma whole sodium (TTX sensitive sodium channels) | |
Cav2.1 | CACNA1A / CACNB3 /CACNA2D2 or CACNA2D4 |
ClC-2 | CLCN2 |
GABAA (α1β2γ2) | GABRA1 / GABRB2 / GABRG2 |
GABAA (α1β3γ2) | GABRA1 / GABRB3 / GABRG2 |
GABAA (α2β2γ2) | GABRA2 / GABRB2 / GABRG2 |
GABAA (α3β2γ2) | GABRA3 / GABRB2 / GABRG2 |
GABAA (α4β3d) | GABRA4 / GABRB3 / GABRD |
GABAA (α5β2γ2) | GABRA5 / GABRB2 / GABRG2 |
GABAA (α6β3d) |
GABRA6 / GABRB3 / GABRD |
Glycine (GlyRα3) |
GLYRA3 |
nAChR (α4β2) | CHRNA4 / CHRNB2 |
nAChR (α7) | CHRNA7 |
Serotonin 5HT3A | HTR3A |
P2X7 | P2RX7 |
AMPA | GRIA1 |
Kainate K2 | GRIK2 |
Kainate K2/K5 | GRIK2/5 |
NMDA (NR1/2A) | GRIN1 / GRIN2A |
NMDA (NR1/2B) | GRIN1 / GRIN2B |
NMDA (NR1 / 2C) | GRIN1 / GRIN2C |
NMDA (NR1/2D) | GRIN1 / GRIN2D |
Memory Panel
GABAA (α5β2γ2) | GABRA5 / GABRB2 / GABRG2 |
AMPA | AMPA1 |
NMDA (NR1 / 2A) |
GRIN1 / GRIN2A |
NMDA (NR1 / 2B) | GRIN1 / GRIN2B |
nAchR (α4β2) | CHRNA4 / CHRNB2 |
nAchR (α7) | CHRNA7 |
Antiepileptic Panel
KV 7.2/7.3 (m current) | KCNQ2/3 |
Kv7.2 | KCNQ2 |
Nav1.1 | SCN1A |
Nav1.2 | SCN2A |
Nav1.3 | SCN3A |
Nav1.6 | SCN8A |
Nav1.7 | SCN9A |
Nav1.8 | SCN10A |
Neuroblastoma whole sodium (TTX sensitive sodium channels) | |
Cav2.1 | CACNA1A / CACNB3 / CACNA2D2 or CACNA2D4 |
ClC-2 | CLCN2 20 |
GABAA (α1β2γ2) | GABRA1 / GABRB2 / GABRG2 |
GABAA (α1β3γ2) | GABRA1 / GABRB3 / GABRG2 |
GABAA (α2β2γ2) | GABRA2 / GABRB2 / GABRG2 |
GABAA (α3β2γ2) | GABRA3 / GABRB2 / GABRG2 |
GABAA (α4β3d) | GABRA4 / GABRB3 / GABRD |
GABAA (α5β2γ2) | GABRA5 / GABRB2 / GABRG2 |
GABAA (α6β3d) | GABRA6 / GABRB3 / GABRD |
GABAA (α1β2γ2) Fluorescence | GABRA1 / GABRB2 / GABRG2 |
Glycine GlyRα3 | GLRA3 |
AMPA | AMPA1 |
NMDA (NR1/2A) | GRIN1 /GRIN2A |
NMDA (NR1/2B) | GRIN1 / GRIN2B |
Pain Panel
GABAA (α1β2γ2) Fluorescence HTS | GABRA1 / GABRB2 / GABRG2 |
GABAA (α1β2γ2) | GABRA1 / GABRB2 / GABRG2 |
GABAA (α1β3γ2) | GABRA1 / GABRB3 / GABRG2 |
GABAA (α2β2γ2) | GABRA2 / GABRB2 / GABRG2 |
GABAA (α3β2γ2) | GABRA3 / GABRB2 / GABRG2 |
GABAA (α4β3d) | GABRA4 / GABRB3 / GABRD |
GABAA (α5β2γ2) | GABRA5 / GABRB2 / GABRG2 |
GABAA (α6β3d) | GABRA6 / GABRB3 / GABRD |
Glycine (GlyRα3) | GLYRA3 |
AMPA | GRIA1 |
NMDA (NR1/2A) | GRIN1 /GRIN2A |
NMDA (NR1/2B) | GRIN1 / GRIN2B |
TRPV1 | TRPV1 (VR1) |
TRPV2 | TRPV2 |
Nav1.7 | SCN9A |
Nav1.8 | SCN10A |